Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00692289

Acronym

RADAR II E

Enrollment

1510

Registered

2008-06-06

Start date

2008-06-30

Completion date

2010-07-31

Last updated

2012-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Quality of Life

Brief summary

This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Provision of informed consent * Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex * Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.

Exclusion criteria

* Allergy to substance of medication * Pre-perimenopausal woman * Woman not eligible for treatment

Design outcomes

Primary

Measure	Time frame
Elements of the investigator questionnaire SF RAND-36 questionnaire	Quarterly (plus or minus 3 days )

Secondary

Measure	Time frame
Investigator Assessment Report	Yearly (plus or minus 1 week )

Countries

Hungary

Outcome results